What FDA Actually Cited in Compounding Enforcement: Q3 2026

FDA's compounding enforcement in 2026 runs in two streams, and most founders only watch one of them. The first goes to pharmacies, and it is about sterility. The second goes to the brands selling the product — telehealth companies, weight-management clinics, direct-to-consumer startups — and it is about what their website says. If you are launching a compounded-medication brand, the second stream is the one aimed at you, and it does not require anyone to inspect your facility, because you do not have one.

What FDA actually cited, at a glance

The third row is the one that surprises people. It is the only one where the finding is made without anyone visiting a building.

Why did four companies receive letters on the same day?

On June 8, 2026, FDA issued warning letters to Maximus Health, Medica Weight Loss, Ready Med and FITISH. None of them is a pharmacy. All four are businesses selling compounded GLP-1 products to consumers, and each letter records that the violations were found during a review of the company's own website: March 2026 for Medica Weight Loss and FITISH, May 2026 for Maximus and Ready Med.

The gap between the review and the letter — one to three months here — matters more than it looks. A website review is not announced, it does not require a complaint, and it can happen at any point while your marketing is live. By the time a letter is written, the copy it quotes has usually been on the page for months, and often still is.

What kind of claim gets cited?

The letters from that day quote the companies' own marketing back to them. The recurring categories:

• Saying or implying that a compounded drug is FDA-approved, or that it has been evaluated by FDA for safety and effectiveness. Compounded drugs are not FDA-approved and have not gone through premarket review.
• Borrowing an approved drug's evidence. Medica Weight Loss was cited over language to the effect that clinical studies and FDA approval support semaglutide's safety and effectiveness — a statement about the approved product, made about a compounded one.
• Describing a supplier as “FDA approved” or “FDA licensed.” Maximus was cited for sourcing claims citing “FDA approved pharmacies” and Ready Med for an “FDA licensed compounding facility.” FDA does not approve or license compounding facilities, whether pharmacies or outsourcing facilities.
• Equivalence claims to a brand-name product, such as Ready Med's references to the same active ingredient in Mounjaro and Zepbound, and in Ozempic and Rybelsus.
• Labeling that implies you compounded the product. Ready Med and FITISH were each cited because the product labels pictured on their websites carried their own name, suggesting they were the compounder when they are not.

The provision behind these is specific: under section 502(bb) of the FD&C Act, a compounded drug is misbranded if its advertising or promotion is false or misleading. It is a claim about the advertising, not about the drug.

Read them together and a pattern falls out: every one of these is a sentence a marketer would write without hesitating, because each sits next to something true. That is what makes this category so easy to walk into.

The last one deserves separate attention from anyone running a branded clinic, because it is the white-label model itself. Putting your brand on the patient experience is ordinary and expected. Putting it on the product label, in a photograph on your own website, is what FDA cited as suggesting you are the compounder when you are not. The dispensing pharmacy is the compounder, the label is theirs, and a product photograph is part of your advertising.

Where does the pharmacy stream fit?

It has not gone away. On September 18, 2026, FDA issued a warning letter to Empower Clinic Services, doing business as Empower Pharmacy, following an inspection of its Houston facility in November 2025. The letter records two kinds of finding: drug products intended or expected to be sterile prepared, packed or held under insanitary conditions such that they may have become contaminated and are adulterated under section 501(a)(2)(A); and products that failed to meet the conditions of section 503A for exemption, including compounding large quantities of a tirzepatide preparation across three months.

FDA has also stated that the insanitary-conditions provision applies regardless of whether the drugs a facility compounds meet the conditions of section 503A. Meeting the exemption is not a defense to how the room was kept.

What changed underneath all of this

The enforcement picture follows a policy one. Several compounding conditions depend on whether a drug appears on FDA's drug shortage list, and the GLP-1 shortages resolved: tirzepatide injection on October 2, 2024, and semaglutide injection afterwards. FDA then set dated windows during which it did not intend to act on violations arising from shortage-dependent conditions, and those windows closed in 2025.

On April 30, 2026, FDA proposed to exclude semaglutide, tirzepatide and liraglutide from the 503B bulks list, on a finding that there is no clinical need for outsourcing facilities to compound them from bulk substances, and took comments through June 29, 2026. That is a proposal rather than a final determination, and this page does not predict the outcome. What it does tell a founder is that the ground under a compounded-GLP-1 product line has moved three times in two years.

What to do about it before the quarter turns

1. 1Read your own landing page as if FDA were reading it, because that is the document under review. Every claim about efficacy, approval, or equivalence to a brand-name drug is in scope.
2. 2Search your site, ad copy, email sequences and affiliate pages for the words approved, clinically proven, FDA, and the brand names of approved GLP-1 products. Those four searches find most of it.
3. 3Remove any description of a pharmacy as FDA-approved or FDA-licensed. If you mean a registered outsourcing facility, say registered, and be able to show the registration.
4. 4Separate what your clinicians decide from what your marketing promises. A claim about outcomes is not made safe by a clinician being involved downstream of it.
5. 5Write down, per product line, which condition your supply actually depends on — a patient-specific prescription, a bulks-list entry, or a shortage that no longer exists.
6. 6Put a recurring date in the calendar to re-read all of it. The copy cited in June 2026 was reviewed in March 2026.

The part most compliance advice leaves out

Almost every published summary of these letters names the company and stops. That is the least useful version of the information, because the name of a business you have never heard of tells you nothing about your own exposure. The finding does. Of the enforcement actions surveyed here, the ones aimed at brands rather than pharmacies were all decided from public marketing copy — which means they were all preventable by a person with a text editor, at any point before the letter was written.

MDLaunchr reviews this as part of onboarding rather than as an add-on, because a launch that gets the clinical and pharmacy side right and the marketing side wrong is still a launch with a problem.

Related reading: 503A vs. 503B compounding and how to choose and verify a telehealth compounding pharmacy.